Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2026-02-23
DOI
https://doi.org/10.1111/apt.70578
Citations
1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
23.38
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

Gema Doménech, Esther Samper, Neus Llarch, Ana Matilla et al.
1 citations
Alimentary Pharmacology & Therapeutics
Hepatocellular Carcinoma Treatment and Prognosis
23.38
article

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

Gema Doménech, Esther Samper, Neus Llarch, Ana Matilla, Gemma Iserte, Loreto Boix, A. J. García Guerrero, M. Heras Fortuny, Francesc Torres, Sergio Muñoz, Jordi Bruix, L. Carrión, Angels Kateb, Maria Reig, Marco Sanduzzi-Zamparelli, Ángeles García-Criado, B. Mínguez, Jordi Rimola, Laura Márquez, Andrés Castaño-García, José Luis Lledo, Mercedes Iñarrairaegui, José Rios-Guillermo
article en
1 citations

Abstract

No abstract available for this paper.
Alimentary Pharmacology & TherapeuticsVol. 63(7)
Universitat Autònoma de Barcelona (ES), Universidad de Oviedo (ES), Hospital General Universitario Gregorio Marañón (ES), Vall d'Hebron Institut de Recerca (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Clínic de Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Hospital Universitario Central de Asturias (ES), Clinica Universidad de Navarra (ES), Institute for Sustainability (GB), Fundació Clínic per a la Recerca Biomèdica (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Hospital Universitario Ramón y Cajal (ES), Universitat de Barcelona (ES)
Good health and well-being
Openalex Percentile: Top 1%
Hepatocellular Carcinoma Treatment and Prognosis
23.38
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.